China Sky One Medical  (中国天字一号医药公司), as we are reminded almost weekly, is a tornado of activity, acquiring companies and bringing out new products at a pace unmatched in China biopharma. Last week, The China Perspective published an interview with Mr. Yan-qing Liu, CEO of China Sky One Medical (see article), an interview that reinforced the company-in-a-hurry theme. Nevertheless, despite its success, the stock remains priced very low relative to its prospects, probably due to the worldwide economic crisis. Using Mr. Lui’s latest interview as an excuse, we would like to take another look at the whirlwind that is China Sky One. More details...

Stock Symbol: (NSDQ: CSKI)